BioNexus Gene Lab Corp (BGLC) Q3 2024 Earnings
BGLC·Reported November 15, 2024·Before market open
BioNexus Gene Lab Corp reported Q3 2024 revenue of $2.6M. Diluted EPS came in at $-0.20.
Revenue
$2.6M
Diluted EPS
$-0.20
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about BioNexus Gene Lab Corp's Q3 2024 earnings report.
BioNexus Gene Lab Corp (BGLC) reported Q3 2024 earnings on November 15, 2024 before market open.
BioNexus Gene Lab Corp reported revenue of $2.6M and diluted EPS of $-0.20 for Q3 2024.
You can read the 10-Q periodic report (0001477932-24-007332) directly on SEC EDGAR. The filing index links above go to sec.gov.